The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 



